P13 An evaluation of vitamin d supplementation to babies on the neonatal unit

2018 ◽  
Vol 103 (2) ◽  
pp. e2.15-e2
Author(s):  
Razmin Begum ◽  
Jiten Modha ◽  
Sian Gaze
Keyword(s):  
Vitamin D ◽  
Daily Intake ◽  
Newborn Infants ◽  
Risk Groups ◽  
Vitamin D Supplementation ◽  
Neonatal Unit ◽  
Milk Formula ◽  
List Type ◽  
Local Policy ◽  
Obstetric Medicine

AimIn 2014, NICE guidance outlined the recommended amount of vitamin D in newborn infants.1 Such deficiency is associated with rickets, hypocalcaemia and seizures.2The aim of this study was to determine whether babies on the neonatal unit received the recommended daily amount of vitamin D by comparing national guidance against our local neonatal policy. To assess how babies obtained their source of vitamin D on the neonatal unit.MethodLocal policy stipulates for pre-term babies<1.8 kg a daily intake of 800–1000 units is recommended and for term babies (>37 weeks) 400 units is recommend. Pre-term and term babies>1.8 kg a dose of 400 units is recommend.Data collected over a 6 week period (1 week pilot study) included prescribed medication, milk volume, milk type (formula or fortifier) and demographics of the patient population. Inclusion criteria: babies with a postnatal age >2 weeks and enteral feeds >120 ml/kg/day. Exclusion criteria: babies with a postnatal age <2 weeks, on TPN, donor breast milk or on demand breast-feeding.Results30 babies identified of, which 21 were classified as pre term and 9 as term. 100% (9/9) of term babies and (3/3) pre-term babies weighing >1.8 kg received the recommended daily vitamin D intake (either as colecalciferol or abidec). The remaining 18 pre-term babies weighing <1.8 kg; 83% (15/18) received the recommended daily intake (either as colecalciferol, abidec, fortifier or milk formula). Overall, from the 30 babies identified in this study 90% (27/30) received their daily recommended intake of vitamin D.ConclusionThis is the first study conducted, which concluded that 90% of babies received the recommend daily intake of vitamin D as outlined in both national and local guidance. It demonstrated that there needs to be a greater focus on vitamin D supplementation on the unit to ensure that all babies are nutritionally optimised.ReferencesNICE Guidelines [PH56]. Vitamin D: Increasing supplement in at-risk groups November 2014.Parisaei M, GovindA, Clements J, etal. Prevalence of vitamin D deficiency in a North London antenatal population. Obstetric Medicine: The Medicine of Pregnancy 2011;4(3):113–116.

Use of Vitamin D and other Dietary Supplements by Finnish Children at the Age of 2 and 3 Years

2004 ◽  
Vol 74 (1) ◽  
pp. 27-34 ◽  
Author(s):  
Marjamäki ◽  
Räsänen ◽  
Uusitalo ◽  
Ahonen ◽  
Veijola ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin A ◽  
Dietary Supplements ◽  
Parental Education ◽  
Daily Intake ◽  
Newborn Infants ◽  
Vitamin D Supplementation ◽  
Birth Cohort Study ◽  
Food Record ◽  
Supplement Use

The aims of this study were to investigate the frequency of the use of vitamin D and other dietary supplements by Finnish children at the age of 2 and 3 years, to evaluate daily nutrient intake from supplements, and to investigate the relation between supplement use and various sociodemographic factors. The families of 534 newborn infants were invited to a birth cohort study in 1996–1997. Families of 292 children at the child's age of 2 years and families of 263 children at the age of 3 years completed a three-day food record from which the daily use of dietary supplements was calculated. The frequency of dietary supplement use was 50% among the two-year-olds, and 37% among the three-year-old children. The most commonly used supplements among the two-year-olds were vitamin D or vitamin A+D combination (38%) and fluoride (16%) and among the three-year-olds fluoride (19%) and multivitamins (16%), respectively. Intake of nutrients other than vitamin D or fluoride from supplements was rare among two-year-olds, whereas 16% of the three-year-olds received also vitamin A, C, E, and several group B vitamins. Mean daily intake of vitamin D from supplements was 6.7 mug at the age of 2 years and 5.3 mug at the age of 3 years, respectively. The level of parental education was positively associated with the child's vitamin D supplementation at the age of 2 years. As the compliance with national recommendations of vitamin D supplementation was low, intensified counseling of the parents is needed at the well-baby clinics in Finland.

scholarly journals Vitamin D monitoring and management within men's secure services

BJPsych Open ◽  
2021 ◽  
Vol 7 (S1) ◽  
pp. S337-S338
Author(s):  
Jason Niblett ◽  
Shay-Anne Pantall ◽  
Anis Ahmed
Keyword(s):  
At Risk ◽  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Treatment Effectiveness ◽  
Average Length ◽  
Vitamin D Insufficiency ◽  
Vitamin D Supplementation ◽  
High Rate ◽  
List Type ◽  
Electronic Patient Records

AimsTo audit the investigation, identification and treatment of Vitamin D deficiency within Men's Secure Services.BackgroundVitamin D and/or vitamin D deficiency has been suggested to play a role in the pathogenesis of mental illness. There is evidence that Vitamin D inadequacy is pandemic among rehabilitation patients in inpatient settings. Patients within secure hospitals are similarly considered to be at high risk, due to their limited solar exposure during often lengthy admissions. It has been suggested that these patients should be considered an ‘at-risk’ cohort, for whom Vitamin D supplementation should be routine. Men's secure services in Birmingham comprise of two medium secure units and a low secure rehabilitation unit. Here we present an audit of Vitamin D monitoring and treatment completed in 2019.MethodA three year retrospective review of electronic patient records, for all inpatients admitted within men's secure services as of 1 September 2019 (n = 188). Standards were based on the Trust accepted guidelines for management of Vitamin D deficiency.ResultKey findings included:- The majority of inpatients were Caucasian (43%) and African-Caribbean (24%). Ages ranged from 18 to 70, with a mean age of 39.Approximately two-thirds (65%) had been in hospital for over a year, of which 44% had been admitted for more than 3 years. The average length of admission was 885 days.Only 47% of patients had their Vitamin D level checked within the study period.Of those checked, 24% were tested within 1 month of admission. The mean duration between admission and Vitamin D testing was 464 days.Results ranged from 10.3 to 118.5nmol/L. A high rate of Vitamin D deficiency was identified (54%), whilst a further 16% had ‘inadequate’ levels.23% of those identified as requiring treatment did not receive any supplementation, whilst 59% of those with sufficient Vitamin D were prescribed treatment.Only 48% had their levels rechecked following treatment; of these, only 59% now had an adequate Vitamin D status.ConclusionThis audit demonstrates limited Vitamin D monitoring within male forensic inpatients. There was a high prevalence of Vitamin D insufficiency in this population, yet a substantial proportion of patients with identified deficiency were not prescribed any treatment. Ongoing monitoring and review of treatment effectiveness was poor. We argue that more consideration should be given to this population, with robust guidelines introduced for the treatment of this specific ‘at-risk group’.

Establishing Benefit from Vitamin D Supplementation — Adherence to Defined Criteria and Targeting of High-Risk Groups Essential?

2020 ◽  
Vol 24 (8) ◽  
pp. 827-831
Author(s):  
Siobhán McGettigan ◽  
P. Mulkerrin ◽  
P. M. O’Shea ◽  
S. T. O’Keeffe ◽  
E. C. Mulkerrin
Keyword(s):  
Vitamin D ◽  
High Risk ◽  
Risk Groups ◽  
Vitamin D Supplementation

scholarly journals Vitamin D in schizophrenia and depression: a clinical review

2019 ◽  
Vol 25 (4) ◽  
pp. 240-248 ◽  
Author(s):  
John Lally ◽  
Fiona Gaughran
Keyword(s):  
Vitamin D ◽  
Mental Disorders ◽  
Physical Health ◽  
Vitamin D Deficiency ◽  
Vitamin D Supplementation ◽  
Research Centre ◽  
List Type ◽  
Potential Association ◽  
Health And Social Care ◽  
Randomised Controlled

SUMMARYEvidence from preclinical and clinical studies supports a role for vitamin D deficiency in many mental disorders. In this review, we discuss the role of vitamin D in the aetiology and treatment of schizophrenia and depression and their physical health comorbidities. Although observational studies support a potential association between vitamin D and schizophrenia and depression, sufficient high-quality evidence from clinical trials does not yet exist to establish a place for vitamin D supplementation in optimising clinical response or promoting physical health. Completed randomised controlled trials are needed to provide insights into the efficacy and safety of vitamin D in the management of mental disorders.LEARNING OBJECTIVESAfter reading this article you will be able to: •outline the epidemiology of vitamin D deficiency in schizophrenia•describe the associations of vitamin D with schizophrenia and depression•know how to assess, and consider treatment for, vitamin D deficiency.DECLARATION OF INTERESTF.G. has received support or honoraria for CME, advisory work and lectures from Bristol-Myers Squibb, Janssen, Lundbeck, Otsuka, Roche and Sunovion, and has a family member with professional links to Lilly and GSK, including shares. She is in part funded by the National Institute for Health Research's (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London and the South London Collaboration for Leadership in Applied Health Research & Care Funding scheme, and by the Maudsley Charity. The views expressed in this article are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

P06 A study to assess the effectiveness of vitamin d supplementation in paediatric cystic fibrosis patients

2018 ◽  
Vol 103 (2) ◽  
pp. e1.9-e1
Author(s):  
Christiansen Nanna ◽  
Ashraf Saleha
Keyword(s):  
Cystic Fibrosis ◽  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Dose Range ◽  
Vitamin D Supplementation ◽  
High Dose ◽  
List Type ◽  
Current Guideline ◽  
Paediatric Patients ◽  
Significant Difference

AimsPatients with cystic fibrosis (CF) require supplementation of fat-soluble vitamins due to the effects of the disease on the pancreas and the resulting inability of absorb fat effectively.1The study aimed to assess the effectiveness of current of vitamin D supplementation to achieve adequate serum Vitamin D (25OHD) levels in paediatric CF patients.2 Secondly, this study assessed the effectiveness of ‘Stoss’ therapy (a high dose vitamin D therapy administered every three months) as an alternative to daily vitamin D supplementation for patients with known poor compliance.3MethodsVitamin D doses and serum 25OHD levels between January and December 2016 were reviewed for paediatric CF patients at a UK centre. Data was collected for 138 paediatric patients. The ‘clinical record summary’ system was used to extract the data which included age, hospital number, weight in 2015 and 2016, 25OHD levels from 2015 and 2016, vitamin D dose before each level and pancreatic status.Data was entered onto Statistical Package for the Social Sciences (SPSS) system for analysis. A paired T-test was conducted to ascertain if there was a significant difference in weekly/kg doses between patients that were sufficient (25OHD>50 nmol/L) and insufficient (25OHD<50 nmol/L).ResultsData was collected for a total of 138 patients. The data from only 70 patients was analysed when investigating the first objective, as all other patients did not have 25OHD levels available for both 2015 and 2016. A further five patients wereexcluded and analysed seperately due to receiving Stoss therapy. The weekly Vitamin D dose range was very wide for both years with 43% (n=40) of patients requiring additional vitamin D in addition to Aquadeks (CF multivitamin preparation). There was no significant difference in Vitamin D doses between patients with sufficient and insufficient 25OHD levels. This was thecase for both 2015 (p=0.432) and 2016 (p=0.192). The daily supplementation doses were successful at maintaining vitamin D sufficiency for 83% of patients in 2015 and 93% in 2016.Out of the 5 patients who received ‘Stoss’ therapy, 3 had an increase in 25OHD levels. However, only one of the patients had a significant increase leading to sufficient 25OHD levels. In 2 cases there was actually a 60%–68% decrease in 25OHD levels, which lead to these patients developing vitamin D deficiency.ConclusionThis study was useful in determining the effectiveness of current Vitamin D dosing. The results suggest that patients having insufficient 25OHD levels may not be due to an inadequacy of doses provided in the current guideline, as there was no significant difference in dose between patients with sufficient and insufficient 25OHD levels. Given the patient group, the difference could be attributable to a lack of compliance to daily therapies in the patients with insufficient 25OHD levels or even differences in individual responses to therapy.In this sample, ‘Stoss’ therapy is not effective in maintaining sufficient 25OHD levels. Although the data for this part of the study was very limited, it identifies a need to investigate the effectiveness of ‘Stoss’ therapy further.ReferencesFerguson JH, Chang AB. Vitamin D supplementation for cystic fibrosis. Cochrane Database of Syst Rev [Internet] 2014. http://onlinelibrary.wiley.com/ & doi:10.1002/14651858.CD007298.pub3/pdf [Available: 2017April 12].Green D, Carson K, Leonard A, et al. Current treatment recommendations for correcting vitamin D deficiency in paediatric patients with cystic fibrosis is inadequate. J Pediatr2008;4:554–559.Shepherd D, Belessis Y, Katz, et al. Single high-dose oral vitamin D3 (stoss) therapy: A solution to vitamin D deficiency in children with cystic fibrosis?J Cyst Fibros2013;2:177–182.

scholarly journals Solar ultraviolet B exposure and global variation in tuberculosis incidence: an ecological analysis

2017 ◽  
Vol 49 (6) ◽  
pp. 1601979 ◽  
Author(s):  
Tjarda M. Boere ◽  
Douwe H. Visser ◽  
A. Marceline van Furth ◽  
Paul Lips ◽  
Frank G.J. Cobelens
Keyword(s):  
Vitamin D ◽  
National Level ◽  
Risk Groups ◽  
Vitamin D Supplementation ◽  
Ultraviolet B ◽  
Tuberculosis Incidence ◽  
Global Variation ◽  
Relevant Variables ◽  
Solar Uv ◽  
Solar Ultraviolet

Epidemiological evidence supports vitamin D deficiency as a risk factor for tuberculosis. Differences in solar ultraviolet B (UV-B) exposure, the major source of vitamin D, might therefore partially explain global variation in tuberculosis incidence.In a global country-based ecological study, we explored the correlation between vitamin D-proxies, such as solar UV-B exposure, and other relevant variables with tuberculosis incidence, averaged over the period 2004–2013.Across 154 countries, annual solar UV-B exposure was associated with tuberculosis incidence. Tuberculosis incidence in countries in the highest quartile of UV-B exposure was 78% (95% CI 57–88%, p<0.001) lower than that in countries in the lowest quartile, taking into account other vitamin D-proxies and covariates. Of the explained global variation in tuberculosis incidence, 6.3% could be attributed to variations in annual UV-B exposure. Exposure to UV-B had a similar, but weaker association with tuberculosis notification rates in the multilevel analysis with sub-national level data for large countries (highestversuslowest quartile 29% lower incidence; p=0.057).The potential preventive applications of vitamin D supplementation in high-risk groups for tuberculosis merits further investigation.

scholarly journals Monthly or Weekly Supplementation with Cholecalciferol 20,000 IU in People Living with HIV: Results from a Nested Cohort Study

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Sebastian Noe ◽  
Christine I. Moeckel ◽  
Christiane Schwerdtfeger ◽  
Celia Oldenbuettel ◽  
Hans Jaeger ◽  
...  
Keyword(s):  
Vitamin D ◽  
Cohort Study ◽  
Vitamin D Deficiency ◽  
Clinical Care ◽  
Daily Intake ◽  
Vitamin D Supplementation ◽  
People Living With Hiv ◽  
Weekly Dose ◽  
Wide Range ◽  
Living With Hiv

Background. There is still considerable uncertainty in handling vitamin D deficiency in people living with HIV (PLWH), due to a lack of comparative data and the wide range of recommended daily intake. Nondaily supplementation might be preferred in many PLWH, but recommendation on dosing has not been established. We aimed to compare the efficacy of weekly versus monthly supplementation with cholecalciferol 20,000 IU in a group of PLWH with vitamin D deficiency in Western Europe. Study Design. Longitudinal, retrospective nested cohort study of PLWH from two large clinical care centers in Munich, Germany. Results. Of 307 patients with vitamin D deficiency, 124 patients received vitamin D supplementation (weekly supplementation in 84 (67.7%)). 46.4% and 22.5% of patients achieved 25(OH)D levels ≥30 ng/mL after 12 months of weekly and monthly supplementation with cholecalciferol 20,000 IU, respectively (p=0.011). Dosing interval as well as 25(OH)D baseline levels >15 ng/mL were associated with the normalization of 25(OH)D. Conclusion. A higher rate of 25(OH)D level normalization can be achieved via weekly supplementation. For several PLWH, even a weekly dose of cholecalciferol 20,000 IU might not be adequate to maintain 25(OH)D levels >30 ng/mL without an initial “loading” dose. The response to supplementation is poorly predictable at an individual level.

Correction of vitamin D deficiency in a cohort of newborn infants using daily 200 IU vitamin D supplementation

2015 ◽  
Vol 185 (3) ◽  
pp. 683-687 ◽  
Author(s):  
C. Onwuneme ◽  
B. Diya ◽  
O. Uduma ◽  
R. A. McCarthy ◽  
N. Murphy ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Newborn Infants ◽  
Vitamin D Supplementation

scholarly journals An Update on Preventive Outlook for Supplementation of Vitamin-D against SARS-CoV-2 Infection

2021 ◽  
Author(s):  
Abu Saim Mohammad Saikat ◽  
Muhammad Torequl Islam
Keyword(s):  
Vitamin D ◽  
Risk Groups ◽  
Vitamin D Supplementation ◽  
Health Interventions ◽  
World Population ◽  
Public Health Interventions ◽  
Pharmacological Agents ◽  
Inflammatory Reactions ◽  
High Death Rate ◽  
High Death

The pandemic COVID-19 has a high death rate, which threatens nearly most of the world's population. The main reason for mortality in severe acute respiratory syndrome is intensified inflammatory activity followed by oxidative stress and inflammatory reactions on the lungs. To date, this pathology does not have a clear and conclusive cure troubling the world population, particularly elderly adults who are the major risk groups. In this sense, assessing the effectiveness of current pharmacological agents, which can be used to resolve or attenuate this pulmonary complication's seriousness that has threatened the lives of so many people globally, is of particular importance. In contrast to quarantine, public health interventions are urgently needed, reducing the risk of illness and death. Evidence reveals that vitamin D supplementation may be possible in treating COVID-19. Additionally, numerous trials and studies started to study the effect of vitamin D supplementation on patients with SARS-CoV-2 infection.

Reassessing vitamin D supplementation in preterm infants: a prospective study and review of the literature

2020 ◽  
Vol 33 (10) ◽  
pp. 1273-1281
Author(s):  
Amnon Zung ◽  
Chani Topf-Olivestone ◽  
Eric S. Shinwell ◽  
Lilach Hofi ◽  
Ada Juster-Reicher ◽  
...  
Keyword(s):  
Vitamin D ◽  
Alkaline Phosphatase ◽  
Preterm Infants ◽  
Daily Intake ◽  
Serum Levels ◽  
Vitamin D Supplementation ◽  
Review Of The Literature ◽  
Significant Elevation ◽  
Total Daily Intake ◽  
A Prospective Study

AbstractObjectivesRecommendations for vitamin D (VitD) intake and target serum levels of 25(OH)D in preterm infants are diverse. We hypothesized that preterm infants with low birth weight (BW) have low dietary intake of VitD and therefore should be supplemented with higher amounts of VitD.MethodsInfants with BW < 2 kg were supplemented with 600 units of VitD a day during the first 2–6 weeks of life, whereas infants with BW>2 kg continued with the routine supplementation of 400 units of VitD daily. Serum levels of 25(OH)D, calcium, phosphorous, alkaline phosphatase (AP) and parathyroid hormone (PTH) were assessed 24 h after birth and before discharge. The total daily intake of vitD was calculated in each infant.ResultsSixty-two infants were enrolled, 49 with BW < 2 kg. After birth, only 24% had sufficient levels of 25(OH)D, whereas before discharge 45 of 54 infants (83%) available for analysis reached sufficient levels of 25(OH)D. All 54 infants demonstrated significant elevation in serum levels of calcium, phosphorous, AP and significant reduction in PTH levels. The total daily intake of VitD was lower than recommended (800–1000 IU/d) in 16 of 45 infants with BW < 2 kg (36%) and in all nine infants with BW>2 kg. Nevertheless, only 2 of 25 infants with insufficient intake of VitD demonstrated insufficient levels of serum 25(OH)D. No case of vitamin D excess was recorded.ConclusionsIncreased supplementation of VitD (600 IU/d) for premature newborns with BW < 2 kg is effective in increasing both total daily intake of VitD and serum levels of 25(OH)D.

Sign in / Sign up

Export Citation Format

Share Document